BNTX · NASDAQ · STOCK
BioNTech SE (BNTX) Stock Analysis
$96.92
52W $79.52 – $124.00
60/100
$24.36B
-12.5
1.25
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is BNTX Bullish or Bearish?
Bullish.
Innellis AI committee rates BioNTech SE (BNTX) Buy with a composite score of 60/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +14.70 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -5.30 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Risk Analyst sees a compelling case — low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock — Risk
Bear Case
- ROE of only -9.1% -- cheap may mean cheap for a reason — Value
- Revenue declining -11.8% YoY -- this is not a growth story right now — Growth
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
- Price structure (HH_HL) contradicts the downtrend -- mixed signals — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
60/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 31%
of 192 Healthcare peers
Value Analyst
bullish
60
/ 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
+ Price-to-book of 1.1x is a discount to asset value
− ROE of only -9.1% -- cheap may mean cheap for a reason
Growth Analyst
neutral
50
/ 100 · Moderate confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− Revenue declining -11.8% YoY -- this is not a growth story right now
Technical Analyst
neutral
47
/ 100 · High confidence
Mixed or range-bound price action
+ Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement
− Price structure making lower highs and lower lows
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
60
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 59.4 to 60.3.
- Conviction changed from moderate to contested.
- Committee agreement fell notably from 67% to 50%.
- Bearish pressure eased: 2 signal(s) disappeared.
- Analyst(s) changed stance: News Analyst.
Analyst-level changes:
- News Analyst: stance bullish->neutral.
- Technical Analyst: score 41->47 (+6).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
50.3
Neutral
MACD Histogram
-0.345
Bearish Momentum
Trend Direction
Downtrend
Weekly: Downtrend
Market Structure
Hh Hl
Support
$91.18
Resistance
$98.79
Bollinger %B
0.43
Inside Bands
Price vs Moving Averages
EMA 9
$96.22
Above
EMA 21
$97.49
Below
EMA 50
$97.74
Below
EMA 200
$97.97
Below
Fundamental Analysis
Valuation
100
Growth
38
Profitability
25
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
-12.5×
P/B Ratio
1.20×
PEG Ratio
0.13
Dividend Yield
0.00%
52W High
$124.00
52W Low
$79.52
Quality & Growth
ROE
-567.9%
ROA
-496.5%
Gross Margin
6894.9%
Operating Margin
-6463.2%
Revenue Growth YoY
—
Debt / Equity
0.02
AI Fundamental Assessment
P/E ratio of -12.5 (inexpensive relative to a 15-40x range); Price-to-book of 1.2x; PEG ratio of 0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -5.7%; Return on assets of -5.0%; Net margin of -64.2%; Gross margin of 68.9%; Current ratio of 7.85 (healthy short-term liquidity); Debt-to-equity of 0.02; Free cash flow per share is positive (2.05); Most recent quarter missed estimates by 51.9%; EPS growth accelerating (-68.0% -> -54.3% QoQ); Analyst estimates falling over recent quarters
Get the Full BNTX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →